报价延迟最少15分钟:2025/08/11 00:37 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.621 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.29/-0.96
|
|
企业价值
70.93M
|
| 资产负债 |
|
每股账面净值
1.95
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/11 00:37 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. |
